Drug Search Results
More Filters [+]

Ceritinib

Alternative Names: ceritinib, ldk378, zykadia
Latest Update: 2024-11-27
Latest Update Note: Clinical Trial Update

Product Description

Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. Ceritinib is a small molecule tyrosine kinase receptor inhibitor and antineoplastic agent that is used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ceritinib)

Mechanisms of Action: ALK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Canada | Chile | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: Lymphoma | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified | Lymphoma | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified

Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation | Diarrhea | Weight Loss

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: BeiGene

Clinical Description

Map of Global Clinical Trials for Ceritinib

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Sarcoma

Phase 2: Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MatchMel

P2

Recruiting

Melanoma

2027-07-01

MULTISARC

P3

Active, not recruiting

Sarcoma

2023-12-31

MCC-19475

P1

Active, not recruiting

Melanoma

2022-10-28

The NCI-NRG ALK Protocol

P2

Active, not recruiting

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer

2021-07-21

Recent News Events